132 Metabolic / Endocrinology CRO and CDMO vendors

What kind of CRO work does a Metabolic / Endocrinology program need?

Metabolic and endocrine programs cover a wide span of biology, and the CRO work changes a lot depending on where you sit in it. A type 2 diabetes or obesity asset, a NASH (now MASH) candidate, a dyslipidemia drug, a thyroid or adrenal program, and a rare endocrine disorder all share some plumbing but ask different questions of a vendor. What ties them together is a heavy reliance on in vivo disease models and a set of physiology readouts that a generalist lab often does not run well, so therapeutic-area depth matters more here than in some other areas.

On the discovery side the work usually starts with target validation and pharmacology in the standard metabolic model toolkit. Diet-induced obese (DIO) mice, db/db and ob/ob mice, Zucker and ZDF rats, streptozotocin-induced diabetes, and high-fat or methionine-choline-deficient diet models for steatohepatitis are the usual workhorses. The readouts are where indication expertise shows: oral and intraperitoneal glucose tolerance tests (OGTT, IPGTT), insulin tolerance tests, hyperinsulinemic-euglycemic clamps (the gold standard for insulin sensitivity and a genuinely hard procedure to run cleanly), body composition by EchoMRI or DEXA, indirect calorimetry for energy expenditure, HbA1c, lipid panels, and food-intake and body-weight tracking over weeks. For NASH you add liver histology with NAS and fibrosis staging, often read by a blinded pathologist, plus emerging non-invasive markers. A lot of the field now runs on incretin biology, so a CRO comfortable with GLP-1, GIP, glucagon, amylin, and dual or triple agonist pharmacology, including PK/PD around peptide half-life and receptor selectivity, is worth seeking out.

Many of these molecules are peptides, antibodies, or other biologics, which pulls CDMO capability into the picture early. That means peptide synthesis or recombinant expression, formulation work for stability and injectability (and increasingly oral peptide delivery), lyophilization, fill-finish, and the analytical methods to support them. On the safety and clinical side you will need IND-enabling tox, then clinical execution that understands endocrine endpoints and the regulatory expectations: cardiovascular outcome considerations for diabetes drugs, glycemic endpoints like HbA1c reduction, weight-loss percentage endpoints for obesity, and the FDA and EMA history around this class. Diabetes and obesity trials also run large and long, so patient access, endocrinology site networks, and central-lab capacity for metabolic assays become real selection criteria.

How do you choose a CRO for Metabolic / Endocrinology?

The screening question is fit to your specific indication and modality, not whether the vendor has a metabolic page on its website. A lab that runs beautiful DIO obesity studies may have never validated a clamp; a NASH histology specialist is the wrong first call for a thyroid program. Put two or three vendors against the same written scope and work the checklist below before you weigh price.

• Therapeutic-area experience: ask for relevant programs in your exact indication (diabetes, obesity, NASH/MASH, dyslipidemia, thyroid or adrenal, rare endocrine) and for the named scientists who would run your work, not just a company track record.
• Disease models and procedures: confirm they actually run the models and readouts you need in-house (DIO, db/db, ZDF, STZ, NASH diet models, OGTT/IPGTT, clamps, indirect calorimetry, body composition) rather than subcontracting the hard parts.
• Incretin and modality fit: for the current wave of GLP-1, GIP, glucagon, and amylin assets, check real experience with peptide and biologic PK/PD, receptor selectivity, and dosing schedules; for CDMO work, confirm peptide or biologic manufacturing, formulation, and stability capability.
• Endpoint and histology quality: for NASH, ask who reads the liver histology and whether scoring is blinded and consistent; for clamps and calorimetry, ask for QC data and historical variability, since these procedures are easy to run badly.
• Regulatory track record: look for prior IND/CTA packages and clinical work in this class, plus awareness of cardiovascular safety expectations for diabetes drugs and the agency history around weight and glycemic endpoints.
• Clinical capacity and patient access: for trials, confirm endocrinology and primary-care site networks, recruitment realism for large long-running studies, and central-lab capability for HbA1c, lipids, and metabolic biomarkers.
• Data quality and capacity: documented SOPs, traceable raw data, GLP status where the study supports a filing, and an honest read on current queue and turnaround so a booked-solid lab does not quietly become your timeline risk.